Zacks Investment Research Upgrades Vical (VICL) to “Hold”

Zacks Investment Research upgraded shares of Vical (NASDAQ:VICL) from a sell rating to a hold rating in a research note issued to investors on Saturday.

According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “

Several other research firms have also recently weighed in on VICL. HC Wainwright restated a buy rating and set a $6.00 price target on shares of Vical in a report on Tuesday, November 21st. ValuEngine cut Vical from a sell rating to a strong sell rating in a report on Friday, September 1st. Finally, Ifs Securities restated an outperform rating on shares of Vical in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $7.50.

Shares of Vical (NASDAQ VICL) opened at $1.80 on Friday. Vical has a 1 year low of $1.66 and a 1 year high of $3.70.

Vical (NASDAQ:VICL) last released its earnings results on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. The business had revenue of $3.24 million for the quarter, compared to analysts’ expectations of $3.60 million. equities analysts predict that Vical will post -1 EPS for the current year.

In other news, Director Robert C. Merton purchased 85,700 shares of the business’s stock in a transaction on Friday, November 10th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $149,975.00. Following the acquisition, the director now directly owns 95,451 shares of the company’s stock, valued at approximately $167,039.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.88% of the company’s stock.

An institutional investor recently raised its position in Vical stock. Renaissance Technologies LLC grew its stake in Vical Incorporated (NASDAQ:VICL) by 6.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 416,029 shares of the biotechnology company’s stock after purchasing an additional 23,520 shares during the period. Renaissance Technologies LLC’s holdings in Vical were worth $932,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 15.46% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Vical (VICL) to “Hold”” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at

Vical Company Profile

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply